Leerink Swann began coverage on shares of Satsuma Pharmaceuticals (NASDAQ:STSA) in a research report released on Tuesday, The Fly reports. The firm issued an outperform rating and a $20.00 price objective on the financial services provider’s stock.
STSA has been the subject of several other reports. Svb Leerink assumed coverage on Satsuma Pharmaceuticals in a research report on Tuesday. They set an outperform rating for the company. Credit Suisse Group assumed coverage on Satsuma Pharmaceuticals in a research report on Tuesday. They set an outperform rating and a $16.00 price objective for the company.
Shares of STSA stock opened at $9.73 on Tuesday. Satsuma Pharmaceuticals has a twelve month low of $9.02 and a twelve month high of $19.90.
About Satsuma Pharmaceuticals
Satsuma Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops a novel therapeutic product for the acute treatment of migraine. Its product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in Phase III clinical trials and can be self-administered with a proprietary pre-filled single-use nasal delivery device.
See Also: Penny Stocks, Risk and Reward Factors
Receive News & Ratings for Satsuma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Satsuma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.